Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4

2(33.3%)

Phase 2

2(33.3%)

N/A

1(16.7%)

Phase 1

1(16.7%)

6Total

Phase 4(2)

Phase 2(2)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05709626Phase 4Recruiting

PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction

Role: lead

NCT04761380Completed

Decreased Tongue Strength is Related to Skeletal Muscle Mass in COPD Subjects

Role: lead

NCT04601441Phase 4Unknown

Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan

Role: lead

NCT03337841Phase 2Unknown

Pembrolizumab as Neoadjuvant Treatment in HCC

Role: lead

NCT01217034Phase 2Unknown

Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib

Role: lead

NCT01360892Unknown

Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography

Role: lead

NCT01360879Unknown

Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease

Role: lead

NCT00822991Not ApplicableUnknown

Sonazoid Enhanced Liver Cancer Trial for Early Detection

Role: lead

NCT00933816Phase 1Completed

Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy

Role: lead

All 9 trials loaded